Business
Golden Valley Development, Inc. Announces the Development of New Healthcare Formulation
Golden Valley Development, Inc. Announces the Development of New Healthcare Formulation.
About this update from Golden Valley Development, Inc.
[{"type":"text","content":"\n \n \n Golden Valley Development, Inc. Announces the Development of New Healthcare Formulation\n \n \nGolden Valley Development, Inc. Announces the Development of New Healthcare Formulation\n\nChronic Pain Reduction Formulation\n\n \n FORT LAUDERDALE, FL--(Marketwired - Apr 22, 2015) - Golden Valley Development, Inc. (OTC PINK: GVDI) (the \"Company\"), a developer and marketer of patented and patentable technologies, is pleased to announce its latest product development in the healthcare sector: An advanced patentable chronic pain reduction formulation. The formula will be available for licensing following testing and release.\n Pain is the leading cause of disability in the US, affecting more than cancer, diabetes and heart disease combined, according to the Life Science Industry Research Report. The global pain therapy and drug market size was over $50 billion in 2013, expected to grow at 10%. Worldwide, there are an estimated 1.5 billion people suffering from chronic pain and chronic pain related symptoms.\n GVDI is in the final testing stages of a proprietary chronic pain reduction formulation. The formula will be available shortly after for licensing. The formula can treat a variety of chronic pain ailments such as Rheumatoid Arthritis. Key active ingredients include polysaccharides, triterpenoids and simple alkylphthalides, extracted and combined using a proprietary deep-heat and sequential isolation process from non-synthetic components. From a limited trial, the results also showed no side effects. More extensive studies and testing are being undertaken for its efficacy and side effects, however, it is believed that there will be no side effects compared to other existing formulas. More extensive studies are continuing, including targeted clinical trials. The formula will initially be for nutraceutical use and will be non-prescription, available over-the-counter, however, the application goes deeper. There will be two methods for application: direct skin application and oral consumption. The oral consumption will come in the form of a flattened square \"gum stick\" coated with thin rice paper, rendering it edible, as well as catalyzing and harmonizing the effect of usage. This is in contrast to the traditional pill/capsule design and method of delivery, which has both a slower activation time and less harmonizing effec...